70 related articles for article (PubMed ID: 19686353)
1. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.
Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Vallejos W; Liang LW; Noga SJ; Rapoport BL
Ann Oncol; 2016 Jan; 27(1):172-8. PubMed ID: 26449391
[TBL] [Abstract][Full Text] [Related]
2. Duration of dexamethasone administration for the prevention of chemotherapy-induced nausea and vomiting - A systematic review and meta-analysis.
Raghunath A; Chandrasekara SD; Anthony SN; Markman B
Crit Rev Oncol Hematol; 2020 Aug; 152():103012. PubMed ID: 32593142
[TBL] [Abstract][Full Text] [Related]
3. Dexamethasone exacerbates cytotoxic chemotherapy induced lethargy and weight loss in female tumor free mice.
Wong J; Tran LT; Lynch KA; Wood LJ
Cancer Biol Ther; 2018 Jan; 19(1):87-96. PubMed ID: 29231783
[TBL] [Abstract][Full Text] [Related]
4. Vomiting after intrathecal chemotherapy under anesthesia in pediatric patients with hematologic cancers: A cohort study.
França de Moraes GH; Lima LC; Couceiro TCM; Lins MM; Cumino DO; Simões LABM; Mello MJG
Paediatr Anaesth; 2024 Jan; 34(1):51-59. PubMed ID: 37727104
[TBL] [Abstract][Full Text] [Related]
5. Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy.
Janowitz T; Kleeman S; Vonderheide RH
Oncologist; 2021 Apr; 26(4):269-273. PubMed ID: 33465258
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the incidence of nausea and vomiting between linezolid and vancomycin using claims database: a retrospective cohort study.
Tsutsumi T; Imai S; Momo K; Kashiwagi H; Sato Y; Sugawara M; Takekuma Y
Int J Clin Pharm; 2024 Apr; 46(2):421-428. PubMed ID: 38158470
[TBL] [Abstract][Full Text] [Related]
7. Anticipatory nausea in animal models: a review of potential novel therapeutic treatments.
Rock EM; Limebeer CL; Parker LA
Exp Brain Res; 2014 Aug; 232(8):2511-34. PubMed ID: 24792499
[TBL] [Abstract][Full Text] [Related]
8. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
9. Oral ondansetron for preventing nausea and vomiting.
Cooke CE; Mehra IV
Am J Hosp Pharm; 1994 Mar; 51(6):762-71. PubMed ID: 8010314
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
Ng WL; Della-Fiorentina SA
Eur J Cancer Care (Engl); 2010 May; 19(3):403-7. PubMed ID: 19686353
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
[TBL] [Abstract][Full Text] [Related]
12. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
14. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
15. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
